Imaging Technology

APRIL 26, 2023

The guideline is published in Practical Radiation Oncology. The guideline emphasizes the need for a multidisciplinary team approach to guide treatment decisions for oligometastatic disease, a description for cancer that reaches a state in which the patient has a small number of metastases in addition to a primary tumor.

Radiation Oncology 97

Radiation Oncology Clinic Radiation Disease 97

Imaging Technology

APRIL 2, 2024

The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states. "We

Healthcare 105

Healthcare Healthcare Radiation Oncology Magnetic Resonance Imaging 105

Imaging Technology

SEPTEMBER 27, 2023

milla1cf Wed, 09/27/2023 - 15:07 September 27, 2023 — The American Society for Radiation Oncology ( ASTRO ) announced the three winning research proposals for the 2022 ASTRO-Myovant Sciences (now known as Sumitomo Pharma)-Pfizer Alliance New Combination (Relugolix-Radiation) Therapy Challenge.

Radiation 105

Radiation Radiation Oncology Clinic Disease 105

Imaging Technology

SEPTEMBER 27, 2023

POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. “PET Gauden , D.Phil.,

Diagnostic 105

Diagnostic Radiation Oncology Radiation Clinic 105

AuntMinnie

JUNE 3, 2024

Eliot Siegel, MD; Stanislav Spiridonov, MD; Nathan Gee, MD; and Anthony Chang, PhD, are among a niche gathering of early adopters, entrepreneurial physicians, medical physicists, and investors with a sweet spot for nuclear medicine, diagnostic radiology, and radiation oncology. led by Harshad Kulkarni, MD, as principal investigator.

Nuclear Medicine 105

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology 105

Imaging Technology

OCTOBER 5, 2023

FDA, POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

Diagnose 52

Diagnose Diagnostic Disease Radiation 52